1Semana·

Symrise: P/E ratio at its lowest level for over 10 years

$SY1 (+1,2 %)


Last year, it seemed as if the share was finally coming back to life, which was logical in view of a 40% jump in profits. In the end, however, the share failed to reach the old highs and has been under pressure ever since.

If you look for a reason for this, you will certainly find one, such as the weak organic growth in the final quarter of 2024 or an ongoing lawsuit in the US due to possible price fixing.

Outlook and valuation

However, the fact that profits rose by 40 % in 2024 is a fact. As is the fact that the share is now trading at the same level as in 2020, although profits are now more than one and a half times higher.

In the first quarter of the current financial year, sales increased organically by 4 % and the forecast was confirmed.

For 2025, Symrise continues to forecast organic growth of 5 - 7 %, an EBITDA margin of 21 % and a free cash flow of 14 %.

Symrise therefore expects solid growth and a slight increase in profitability.

This is in line with the consensus estimates, which predict an 11 % jump in earnings to EUR 3.82 per share for the current fiscal year.

Accordingly, Symrise has a P/E ratio of 23.7, which is reasonable in view of the double-digit growth rates. The long-term average P/E ratio is 30.


complete article:


https://www.lynxbroker.de/boerse/boerse-kurse/aktien/symrise-aktie/symrise-analyse/?a=3355991664&utm_medium=email&utm_source=newsletter&utm_campaign=newsletter-boersenblick&newsletter=true&mc-rss-cache-bypass=2025070706&goal=0_d93daae099-e2cc65abd4-410756260#symrise-kgv-auf-dem-niedrigsten-niveau-seit-ueber-10-jahren

previw image
5
4 Comentarios

Imagen de perfil
"The fragrance and flavor manufacturer Symrise increased sales organically by 4.2% to EUR 1.3 billion in Q1. This is less than Peer Givaudan's 7.4%, which also suffered from slightly weaker momentum at the start of the year. However, analysts had expected less from Symrise overall.

It is important that the organic growth was mainly driven by higher sales volumes, which underlines the continuing high demand, particularly in the EAME (Europe, Africa, Middle East) and Asia/Pacific regions. Management has therefore confirmed the forecast for 2025 with organic sales growth of 5 to 7% and an EBITDA margin of 21%. By comparison, Givaudan is targeting 4 to 5% organic sales growth and an EBITDA margin of 22 to 24%."
3
Imagen de perfil
looks like a clear buy to me
but you can't have everything
1
Imagen de perfil
Perhaps wait for chart stabilization, otherwise attractive zone right now
1
Imagen de perfil
I had Symrise on my radar before the correction and got in small, now to my regret and with a loss of almost 13%. However, I expect more from you and therefore the savings plan is simply running
1
Únase a la conversación